another loi signed for myoconda..

Hey there whoever is reading this, possibly no-one except maybe skippa if your still holding..

Ann follows, and is another step on the road to commercial success.

The price reflects a lack of excitement, which was never going to be an instant success story, however, as soon as we get FDA approval, we will see $2.00 overnight.

See you skip, and may be one or 2 others..






GIACONDA RECEIVES SECOND NON-BINDING LOI FOR COMMERCIALISATION OF
MYOCONDA®
Sydney, Australia. 1 August 2006. Giaconda Limited (ASX: GIA) today announced that it has
received a non-binding letter of intent (LOI) from Orphan Australia Pty Limited regarding the licensing
and commercialisation of its lead product for Crohn’s disease, Myoconda®.
In this LOI Orphan Australia has expressed its intention to undertake due diligence with the objective
of acquiring the exclusive rights to commercialise Myoconda® in Australia, South Africa, Namibia and
Asia. Licensing agreement discussions will commence when Giaconda obtains an IND
(Investigational New Drug) from the US Food and Drug Administration (FDA), which is expected later
this year.
“We are delighted to have signed this LOI with Orphan Australia for the commercialisation of our lead
product,” said Patrick McLean, CEO of Giaconda. “Giaconda is committed to commercialising
Myoconda® by choosing the most appropriate partners for each territory. The Orphan Australia sales
force already calls on Australian gastroenterologists and has an excellent understanding of their
needs as well as Crohn’s Disease itself.” he added.
Crohn’s disease affects over 30,000 people in Australia. Research shows that the number of people
with Crohn’s disease has been rising steadily, particularly among young people.
“The commercialisation of Myoconda® will give us an opportunity to provide alternative treatment to a
patient group that fails treatment with conventional therapies,” commented Mr. John Michailidis, Chief
Operating Officer of Orphan Australia.
About Giaconda Limited
Giaconda Limited is a biotechnology company involved in developing and licensing innovative and
cost effective medical therapies in the field of gastroenterology. Giaconda’s products are targeted
towards the treatment of serious conditions that are not adequately addressed by any existing
therapy. In this way, Giaconda’s products are intended to satisfy these significant unmet medical
needs of the gastrointestinal market. The Giaconda portfolio consists of five products, all of which are
novel combinations of known compounds. Giaconda has two lead products, Myoconda® for the
treatment of Crohn’s Disease and Heliconda® for the treatment of resistant Helicobacter pylori
infection. Both of these products are ready for Phase III clinical trials, with a Phase IIIa already
complete for Myoconda®.


About Orphan Australia Pty Limited
Orphan Australia is a privately owned pharmaceutical company based in Melbourne, providing niche
products to Australia, New Zealand and selected South East Asian countries. Orphan Australia
specialises in the development, marketing and distribution of products typically used by specialists to
treat serious and/or life threatening disorders where current therapy is either unavailable or
inadequate.